NCT06979596 2026-03-06
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
10 trialsNCT05645536 2026-01-12
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Tolmar Inc.
Phase 3 Enrolling by invitation
NCT02093351 2019-10-02
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
AstraZeneca
Phase 1 Completed
NCT01685255 2019-03-11
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
Incyte Corporation
Phase 2 Terminated
NCT00206492 2017-08-01
Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients
Baylor Breast Care Center
Phase 2 Terminated
NCT02513849 2017-05-09
Tamoxifen in Patients With Oesophageal Cancer
University of Nottingham
Phase 1 Unknown
NCT00108069 2015-11-05
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00605267 2012-09-06
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
AstraZeneca
Phase 3 Completed
NCT00189358 2010-07-20
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
AGO Study Group
Phase 2 Completed
NCT00034125 2006-07-19
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
Eli Lilly and Company
Phase 3 Completed